JNJ

Johnson & Johnson’s Single-Dose Coronavirus Vaccine Enters Late-Stage Trials
Johnson & Johnson’s Single-Dose Coronavirus Vaccine Enters Late-Stage Trials
Forbes
JNJ
vaccines
clinical trials
COVID-19
Flag link:
Genmab and Janssen Head to Arbitration Table Over Darzalex Royalties
Genmab and Janssen Head to Arbitration Table Over Darzalex Royalties
BioSpace
Genmab
JNJ
Janssen
Darzalex
arbitration
Multiple Myeloma
Flag link:
ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga
ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga
Fierce Biotech
Roche
prostate cancer
ESMO
JNJ
Ipatasertib
Zytiga
Flag link:
New York Files Charges Against Johnson & Johnson Over Opioid Marketing
New York Files Charges Against Johnson & Johnson Over Opioid Marketing
Motley Fool
JNJ
New York
opioids
opioid crisis
patients
Flag link:
Janssen files Darzalex Faspro for rare disease light chain amyloidosis
Janssen files Darzalex Faspro for rare disease light chain amyloidosis
Pharmaforum
JNJ
Janssen
Darzalex Faspro
light chain amyloidosis
Flag link:
COVID-19 vaccine CEOs vow to wait for phase 3 data before filing for approval
COVID-19 vaccine CEOs vow to wait for phase 3 data before filing for approval
Fierce Pharma
COVID-19
vaccines
Operation Warp Speed
Donald Trump
AstraZeneca
Pfizer
BioNTech
GSK
JNJ
Merck
Moderna Therapeutics
Novavax
Sanofi
Flag link:
Big pharma spinouts grow up
Big pharma spinouts grow up
EP Vantage
Big Pharma
spinoffs
Merck KGaA
Pfizer
GSK
Novartis
Roche
Sanofi
JNJ
AstraZeneca
Flag link:
Janssen gets expanded EC nod for blood cancer combo drug Imbruvica plus rituximab
Janssen gets expanded EC nod for blood cancer combo drug Imbruvica plus rituximab
Pharmaceutical Business Review
JNJ
Janssen
Europe
Imbruvica
rituximab
CLL
Flag link:
Johnson & Johnson Aiming to Enroll One-Third of Phase 3 Trial Patients From Latin America
Johnson & Johnson Aiming to Enroll One-Third of Phase 3 Trial Patients From Latin America
Motley Fool
JNJ
Latin America
clinical trials
vaccines
COVID-19
Flag link:
Johnson & Johnson Coronavirus Vaccine Candidate Shows Encouraging Results in Animal Trial
Johnson & Johnson Coronavirus Vaccine Candidate Shows Encouraging Results in Animal Trial
Motley Fool
JNJ
vaccines
COVID-19
clinical trials
Ad26.COV2-S
Flag link:
As Covid research heats up, J&J retires a BARDA-funded flu antiviral they worked on for 7 years
As Covid research heats up, J&J retires a BARDA-funded flu antiviral they worked on for 7 years
Endpoints
JNJ
pandemic
COVID-19
antivirals
BARDA
pimodivir
Flag link:
J&J, free from rival bidders, made Momenta wait on $6.5B deal
J&J, free from rival bidders, made Momenta wait on $6.5B deal
Fierce Biotech
JNJ
Momenta Pharmaceuticals
M&A
Flag link:
US urged to criminally charge Sackler family, other pharma execs for opioid crisis
US urged to criminally charge Sackler family, other pharma execs for opioid crisis
Beckers Hospital Review
opioids
opioid crisis
Sackler family
Purdue Pharma
AmerisourceBergen
Cardinal Health
McKesson
JNJ
Mallinckrodt
Flag link:
New data from J&J, Arrowhead mark latest step in RNAi's hepatitis B race
New data from J&J, Arrowhead mark latest step in RNAi's hepatitis B race
BioPharma Dive
Arrowhead Pharmaceuticals
JNJ
clinical trials
RNAi
hepatitis B
Flag link:
Why Novavax's Coronavirus Vaccine Might Be First to Market
Why Novavax's Coronavirus Vaccine Might Be First to Market
Motley Fool
FDA
Novavax
JNJ
Moderna Therapeutics
AstraZeneca
vaccines
COVID-19
clinical trials
Emergency Use Authorization
Flag link:
J&J to start mid-stage coronavirus vaccine trials in three European countries
J&J to start mid-stage coronavirus vaccine trials in three European countries
Reuters
JNJ
Janssen
vaccines
COVID-19
clinical trials
Europe
Spain
The Netherlands
Germany
Flag link:
BARDA and JLABS Pick 7 Startups to Battle COVID-19 and Future Pandemics
BARDA and JLABS Pick 7 Startups to Battle COVID-19 and Future Pandemics
BioSpace
Blue Knight
JLabs
BARDA
JNJ
pandemic
COVID-19
Flag link:
J&J's RNAi suppresses hepatitis B for 48 weeks after last dose
J&J's RNAi suppresses hepatitis B for 48 weeks after last dose
Fierce Biotech
JNJ
RNAi
JNJ-3989
hepatitis B
Flag link:
EASL 2020 – Assembly finds a partner as hepatitis B inches forward
EASL 2020 – Assembly finds a partner as hepatitis B inches forward
EP Vantage
EASL
RNAi
hepatitis B
Assembly Biosciences
Abrutus
JNJ
GSK
Vir Biotechnology
Flag link:
FDA pulls J&J's Invokana boxed warning after reviewing amputation risks—but the sales damage is done
FDA pulls J&J's Invokana boxed warning after reviewing amputation risks—but the sales damage is done
Fierce Pharma
JNJ
Invokana
diabetes
amputation
black box
Flag link:

Pages